IDH1/2 mutations are predominantly associated with lower-grade glioma, and it may be the case that endogenous R-2HG production in GSCs suppresses FTO levels, thus reducing oncogene expression and limiting progression by maintaining m6a levels. This evidence concerns the gene IDH1 and central nervous system cancer.